An interim analysis shows that Roche’s (ROG: SIX) Phase III IMpower150 study has met its co-primary endpoint of overall survival (OS).
The trial is exploring a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemo to treat non-squamous non-small cell lung cancer (NSCLC) in the first-line setting.
The triple combo, which is being compared with Avastin and chemo alone, showed a survival benefit across key subgroups, including those with varying levels of PD-L1 expression. No new safety signals were detected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze